Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) EBT Margin (2016 - 2025)

Corcept Therapeutics' EBT Margin history spans 10 years, with the latest figure at 4.9% for Q4 2025.

  • For Q4 2025, EBT Margin fell 1267.0% year-over-year to 4.9%; the TTM value through Dec 2025 reached 8.73%, down 1519.0%, while the annual FY2025 figure was 8.73%, 1519.0% down from the prior year.
  • EBT Margin for Q4 2025 was 4.9% at Corcept Therapeutics, down from 7.34% in the prior quarter.
  • Across five years, EBT Margin topped out at 37.77% in Q3 2021 and bottomed at 4.9% in Q4 2025.
  • The 5-year median for EBT Margin is 26.29% (2023), against an average of 24.16%.
  • The largest annual shift saw EBT Margin skyrocketed 841bps in 2021 before it tumbled -2166bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 37.17% in 2021, then plummeted by -37bps to 23.56% in 2022, then increased by 15bps to 27.18% in 2023, then plummeted by -35bps to 17.57% in 2024, then plummeted by -72bps to 4.9% in 2025.
  • Per Business Quant, the three most recent readings for CORT's EBT Margin are 4.9% (Q4 2025), 7.34% (Q3 2025), and 16.3% (Q2 2025).